
Kamada Ltd is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutics for the treatment of respiratory diseases.
The company's business operations are led by Amir London, its President and Chief Executive Officer.
Kamada Ltd has a portfolio of products that includes AeroLEF, a bronchodilator for the treatment of acute bronchospasm, and Inhale, a platform technology for the delivery of therapeutic proteins and peptides.
AeroLEF has received FDA approval for the treatment of acute bronchospasm and is also available in several other countries.
See what others are reading: Deferred Compensation Tax Treatment for Employer
Stock Information
Kamada Ltd. is a company that manufactures and sells plasma-derived protein therapeutics.
Their stock, KMDA, is currently trading at 79.8% below its estimated fair value.
Kamada's financial health is quite strong, with a Snowflake Score of 6/6.
Here's a quick snapshot of Kamada's historical stock prices:
Their stock price has fluctuated over time, with a 52 week high of ₪9.16 and a 52 week low of ₪5.18.
Expand your knowledge: How to Write a 2 Week Notice
Stock Information
Kamada's stock is a plasma-derived protein therapeutic manufacturer, which means it's in the biotech industry.
Their current share price is ₪6.84, which is significantly lower than their estimated fair value, trading at 79.8% below.
The 52-week high for Kamada's stock was ₪9.16, while the 52-week low was ₪5.18.
Kamada's beta is 0.059, indicating that their stock price is relatively stable compared to the market.
Here's a summary of Kamada's price history:
Kamada's weekly volatility is 4.2%, which is relatively low compared to the biotechs industry average of 10.3% and the market average of 6.4%.
Shareholder Returns
When looking at shareholder returns, it's essential to consider the performance of a company in relation to its industry and the broader market. KMDA has exceeded the US Biotechs industry, which returned 0.1% over the past year.
KMDA's 1-year return of 31.0% is significantly higher than the US Market's 17.8% return over the same period.
A comparison of shareholder returns can be seen in the following table:
This data shows that KMDA's 7-day return of 0% is lower than both the US Biotechs industry and the US Market, but its 1-year return is significantly higher than both.
Operations and Updates
Kamada Ltd. has a strong commitment to quality and compliance, with a dedicated team in place to ensure all products meet the highest standards.
The company is headquartered in Israel and has a subsidiary in the United States, with a presence in other countries as well.
Kamada Ltd. has a robust quality control process in place, with regular audits and inspections to guarantee the quality of its products.
The company's manufacturing facilities are designed to meet the highest international standards, with a focus on efficiency and productivity.
Kamada Ltd. has received numerous regulatory approvals for its products, including FDA approval in the United States and CE marking in Europe.
For more insights, see: Banking Codes and Standards Board of India
Products and Research
Kamada Ltd. has developed a technological platform for the production of specific immunoglobulins (IgG's), including a product for the treatment of HDN – a disease caused from Rh negative in the fetus. This product is manufactured from the serum of hyper-immune horses.
The company also produces a specific antibody against the rabies virus, as part of its product portfolio. This antibody is used for post-exposure prophylaxis, a treatment for individuals who have been exposed to the rabies virus.
Kamada's product portfolio features critical care pharmaceuticals delivered via injection, infusion, and inhalation, as well as antiserums for treating snake bites.
See what others are reading: Cambridge Antibody Technology
Products and Research
Kamada Pharmaceuticals has developed a technological platform for the production of specific immunoglobulins (IgG's), including a product for the treatment of HDN (Hemolytic Disease of the Newborn) caused by Rh negative in the fetus.
The company produces a specific antibody against the rabies virus and has a product for the treatment of HDN, a disease caused by Rh negative in the fetus. It also manufactures serum against snake venom from the serum of hyper-immune horses.
Kamada Pharmaceuticals has a strategic agreement with Kedrion Pharmaceuticals for the development and marketing of the KamRab rabies immunoglobulin in the United States.
Recommended read: Collateral Loan against Property

The company's product portfolio features critical care pharmaceuticals delivered via injection, infusion, and inhalation, as well as antiserums for treating snake bites.
Here is a list of some of Kamada's marketed drugs:
- Product for the treatment of HDN (Hemolytic Disease of the Newborn)
- Antibody against the rabies virus
- Serum against snake venom
- Product for the treatment of ITP (Immune Thrombocytopenic Purpura)
- Post-exposure prophylaxis
- Alpha-1 Antitrypsin (AAT) deficiency treatment
Kamada Pharmaceuticals is developing a plasma-derived Hyperimmune IgG therapy for COVID-19, an Inhaled AAT program, and is also in early-stage development of recombinant AAT and liquid AAT for organ preservation.
Clinical Trials
Kamada Pharmaceuticals' clinical trials are a crucial aspect of their business, and understanding their approach can be insightful. They determine their go-to-market proposition, which is a critical factor in the success of their products.
Their clinical operations are well-structured, with a clear strategy for recruitment and trial management. This approach helps them to efficiently conduct trials and gather valuable data.
By gaining insight into their clinical trials, investors and stakeholders can better understand the company's growth potential. This information can also help them to make informed decisions about investing in the company's products.
Pharma Industry Data & Analytics
Kamada Ltd. has a strong presence in the pharma industry, and its data and analytics play a crucial role in this. The company has a significant market share in the US and Europe, with its products being sold in over 40 countries.
Kamada's focus on plasma-derived therapeutics has led to the development of several innovative products. Its product portfolio includes Aerius, a recombinant human hyaluronidase enzyme that facilitates the administration of other drugs.
The company's commitment to research and development has led to the filing of several new drug applications with the FDA. This includes an NDA for a recombinant human alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency.
Kamada's products have shown promising results in clinical trials, with Aerius demonstrating improved drug absorption and reduced administration time in patients. This has significant implications for patients with conditions that require frequent injections.
The company's partnerships and collaborations have also been instrumental in its growth. For example, its partnership with Shire has led to the development of a recombinant human hyaluronidase enzyme for the administration of other drugs.
Kamada's financial performance has been strong, with revenue growth of over 50% in the past year. This is a testament to the company's successful business model and its ability to execute on its strategy.
Intriguing read: Strong Dollar Policy
Consider reading: Orion Pharma Ltd.
Frequently Asked Questions
Is kamada stock a buy?
Kamada stock holds a buy signal from the short-term Moving Average, but a general sell signal from the long-term average. This mixed signal may indicate a near-term buying opportunity, but further analysis is recommended.
Who owns Kamada?
Kamada is primarily owned by FIMI Opportunity Funds, a leading private equity firm in Israel, which holds approximately 38% of the company's outstanding shares.
Featured Images: pexels.com


